Background: In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological …

2017年7月13日 · The addition of pertuzumab to trastuzumab–docetaxel neoadjuvant treatment for 12 weeks in the randomized, multicenter, open-label NeoSphere trial resulted in a significant …

2016年5月11日 · In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological …

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, …

2011年12月7日 · In the NeoSphere study, following only four cycles of neoadjuvant treatment, pertuzumab and trastuzumab plus docetaxel resulted in complete tumour eradication in the …

2015年5月20日 · Results: Three-year survival rates, hazard ratios (HRs), and 95% CIs for the main analysis of P+T+D compared with T+D are summarized in the table. In the P+T and P+D …

2017年2月9日 · NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus …

2015年2月19日 · In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first …

2016年5月19日 · A 5-year follow-up of the phase II NeoSphere trial confirmed that patients with HER2-positive breast cancer receiving a 3-drug neoadjuvant pertuzumab regimen had better …

2017年2月9日 · We assessed associations between human epidermal growth factor receptor 2 (HER2) pathway-related biomarkers and clinical outcome in response to these regimens. …